v3.26.1
Segment and Geographic Data
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
We segregate our operations into two reportable business
segments: (i) MedSurg and Neurotechnology and (ii)
Orthopaedics which aligns to our internal reporting structure and
how our Chief Operating Decision Maker (CODM) assesses the
performance and allocates resources. The CODM is the Chief
Executive Officer. The CODM makes decisions on resource
allocation, assesses performance of the business, and monitors
budget versus actual results using segment operating income.
Information about total assets by segment is not disclosed
because such information is not regularly provided to, or used by,
our CODM.
Segment Results
Three Months
Six Months
2026
2025
2026
2025
MedSurg and Neurotechnology
$3,625
$3,305
$6,832
$6,361
Orthopaedics
2,964
2,717
5,777
5,527
Net sales
$6,589
$6,022
$12,609
$11,888
MedSurg and Neurotechnology
$1,343
$1,264
$2,634
$2,438
Orthopaedics
822
767
1,661
1,556
Cost of sales
$2,165
$2,031
$4,295
$3,994
MedSurg and Neurotechnology
$255
$228
$486
$437
Orthopaedics
155
153
309
318
Segment research, development and
engineering expenses
$410
$381
$795
$755
MedSurg and Neurotechnology
$945
$909
$1,873
$1,768
Orthopaedics
850
781
1,695
1,669
Segment selling, general and
administrative expenses
$1,795
$1,690
$3,568
$3,437
MedSurg and Neurotechnology
$63
$58
$120
$114
Orthopaedics
129
116
258
230
Segment depreciation and
amortization
$192
$174
$378
$344
Corporate and Other
$37
$26
$66
$53
Amortization of intangible assets
175
187
355
354
Total depreciation and amortization
$404
$387
$799
$751
MedSurg and Neurotechnology
$1,019
$846
$1,719
$1,604
Orthopaedics
1,008
900
1,854
1,754
Segment operating income
$2,027
$1,746
$3,573
$3,358
Items not allocated to segments:
Corporate and Other
$(220)
$(201)
$(495)
$(469)
Inventory stepped up to fair value
(65)
(99)
Acquisition and integration-related
charges
(25)
(78)
(44)
(263)
Amortization of intangible assets
(175)
(187)
(355)
(354)
Structural optimization and other special
charges
(95)
(11)
(213)
(52)
Goodwill and other impairments
(1)
(55)
(1)
(90)
Medical device regulation
(5)
(7)
(10)
(19)
Recall-related matters
(2)
(22)
(12)
(55)
Regulatory and legal matters
(3)
(7)
(6)
(7)
Reversal of 2025 tariffs
158
158
Consolidated operating income
$1,659
$1,113
$2,595
$1,950